Navigation Links
Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
Date:7/22/2009

al, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not receive some or all of the future milestone payments or royalties, the risk that the program does not have significant upside potential and the risk that sales of anti-VEGF antibodies do not achieve the levels projected by some market analysts. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release

    Contacts:

    Peregrine Pharmaceuticals Inc
    Investors                          
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.; Affitech A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Portage Biotech Inc. ("Portage" or "the Company") (OTC Market: ... that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. (PPL) ... Investigational New Drug (IND) application for the topical treatment ... a study in a rat model of dry eye ... and a more rapid onset of action than 0.1% ...
(Date:8/31/2015)... and SHANGHAI , ... privately-held biopharmaceutical company developing next-generation antibiotics, today announced ... clinical study for its lead drug candidate MRX-I. ... treat drug-resistant bacteria such as MRSA and VRE, ... better tolerated therapeutic option than currently available oxazolidinone ...
(Date:8/31/2015)... Aug. 31, 2015 Trimb Healthcare AB ("Trimb") ... acquire YouMedical Group BV ("YouMedical"), a Dutch OTC company ... annual sales of approximately EUR 16 million, with solid ... "Our ambition is to build a leading international ... toward that goal. YouMedical gives us a stronger North ...
(Date:8/31/2015)... ... 2015 , ... There’s a new treatment option for excessive menstrual bleeding – ... FDA approved system in the last 14 years, and the only endometrial ablation product ... rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest procedure ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Aug. 15 BioMaxx Systems Inc. (Other,OTC: BMXSF), ... engagement letter with,Alcofuel Technologies Ltd., for the provision ... micro-refinery. Pursuant to the engagement,letter, Alcofuel Technologies has ... engagement letter, to design and manufacture a small,scale ...
... Inc. (Nasdaq: ADLS ), today announced that ... informed the Company that the,market value of its ... days, which is the requirement for continued listing ... 4450(b)(1)(A). Nasdaq,also informed the Company that it is ...
... - AEterna Zentaris Inc.,(TSX: AEZ; NASDAQ: AEZS), a ... today announced the filling of a key,position completing ... Blake,M.D., as Senior Vice President and Chief Medical ... timely and critical as our foremost,priority is to ...
Cached Biology Technology:BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4AEterna Zentaris completes management team with the appointment of Chief Medical Officer 2AEterna Zentaris completes management team with the appointment of Chief Medical Officer 3
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... launch of SAFmodule(TM) 3.1 SP3 to expand ... authentication methods, AUSTIN, Texas, Sept. 20 ... biometric authentication to Novell(R) eDirectory,networks by coupling ... Authentication Service (NMAS(TM)) security framework. NMAS,is a ...
... of computer scientists, mathematicians, and biologists from around the ... trace the genetic ancestry of thousands of individuals in ... teams findings will be published in the September 2007 ... computer programs of its kind that require prior knowledge ...
... results of a recent National Academy of Sciences report, ... be restored to the U.S. Department of Energy, says ... nuclear medicine professionals. Funded by the Department of ... $700,000 report was prompted by a $23 million cut ...
Cached Biology News:IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks 2Computer program traces ancestry using anonymous DNA samples 2SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: